National Heart and Lung Institute, Imperial College London, London, UK
Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
BMJ Open. 2023 Mar 7;13(3):e065927. doi: 10.1136/bmjopen-2022-065927.
To describe prevalence of chronic kidney disease (CKD), demographic and clinical characteristics, treatment patterns and rates of cardiovascular and renal complications for patients with type 2 diabetes (T2D) treated in routine clinical care.
Repeat cross-sectional study (6 monthly cross-sections) and cohort study from 1 January 2017 to 31 December 2019.
Primary care data from English practices contributing to the UK Clinical Practice Research Datalink linked to Hospital Episode Statistics and Office for National Statistics mortality data.
Patients with T2D aged >18 years, at least one year of registration data.
Primary outcome was prevalence of CKD defined as chronic kidney disease epidemiology collaboration (CKD-EPI) estimated glomerular filtration rate <60 mL/min/1.73 m, and/or urinary albumin creatinine ratio ≥3 mg/mmol in the past 24 months. Secondary outcomes were prescriptions of medications of interest and clinical and demographic characteristics in the past 3 months.In the cohort study rates of renal and cardiovascular complications, all-cause mortality and hospitalisations over the study period were compared among those with and without CKD.
There were 574 190 eligible patients with T2D as of 1 January 2017 and 664 296 as of 31 December 2019. Estimated prevalence of CKD across the study period was stable at approximately 30%. Medication use was stable over time in people with CKD and T2D, with low use of steroidal mineralocorticoid receptor antagonists (approximately 4.5% across all time points) and a low use but steady increase in use of sodium-glucose co-transporter-2 inhibitors (from 2.6% to 6.2%). Rates of all complications were higher in those with CKD at the start of the study period, with increasing rates, with increased severity of CKD, heart failure and albuminuria.
The burden of CKD in patients with T2D is high and associated with substantially increased rates of complications particularly in those with comorbid heart failure.
描述在常规临床护理中接受治疗的 2 型糖尿病(T2D)患者的慢性肾脏病(CKD)患病率、人口统计学和临床特征、治疗模式以及心血管和肾脏并发症的发生率。
重复横断面研究(6 个月的横断面)和队列研究,时间为 2017 年 1 月 1 日至 2019 年 12 月 31 日。
来自参与英国临床实践研究数据链接的英语实践的初级保健数据,该数据链接与医院发病统计数据和国家统计局死亡率数据相关联。
年龄>18 岁、注册数据至少一年的 T2D 患者。
主要结局是在过去 24 个月内使用慢性肾脏病流行病学合作(CKD-EPI)估计肾小球滤过率<60ml/min/1.73m2和/或尿白蛋白肌酐比≥3mg/mmol 定义的 CKD 患病率。次要结局是在过去 3 个月内使用感兴趣的药物和临床及人口统计学特征。在队列研究中,比较了研究期间有和无 CKD 的患者的肾脏和心血管并发症、全因死亡率和住院率。
截至 2017 年 1 月 1 日,有 574190 名符合条件的 T2D 患者,截至 2019 年 12 月 31 日,有 664296 名符合条件的 T2D 患者。在整个研究期间,CKD 的估计患病率稳定在约 30%。在患有 CKD 和 T2D 的人群中,药物使用随时间保持稳定,甾体类盐皮质激素受体拮抗剂的使用率较低(所有时间点均约为 4.5%),而钠-葡萄糖协同转运蛋白-2 抑制剂的使用率较低但呈稳步上升趋势(从 2.6%升至 6.2%)。在研究开始时患有 CKD 的患者中,所有并发症的发生率较高,随着 CKD、心力衰竭和白蛋白尿的严重程度增加,发生率也在增加。
T2D 患者的 CKD 负担很高,与并发症的发生率显著增加相关,尤其是与合并心力衰竭的患者。